Law360 (April 13, 2018, 8:20 PM EDT) -- Indirect buyers of Aggrenox told a Connecticut federal judge Friday that attorneys who represented the putative class alleging that Teva Pharmaceutical and Boehringer Ingelheim blocked generic alternatives to the stroke-prevention drug from coming to the market should get $18 million of the proposed $54 million settlement.
The putative class said the firms Miller Law LLC, Heins Mills & Olson PLC and Hilliard & Shadowen LLP should take a third of the settlement because the litigation was complex, involved nearly 41,000 hours of work and was risky...
Aggrenox End-Payors Want $18M Atty Fees In $54M Deal
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
